Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia

Asian Journal of Andrology

Volumn 12, Issue 5, 2010, Pages 690-696

  Yoo, Koo Han ^a   Kim, Su Kang ^b   Chung, Joo Ho ^b   Chang, Sung Goo ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

benign prostatic hyperplasia; nitric oxide synthase 2; single nucleotide polymorphism

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; COHORT STUDIES; HUMANS; KOREA; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA;

EID: 77956427577     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.37     Document Type: Article

References (29)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71.
2. Park HK, Park H, Cho SY, Bae J, Jeong SJ, et al. The prevalence of benign prostatic hyperplasia in elderly men in Korea: a community-based study. Korean J Urol 2009; 50: 843-7.
3. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-16.
4. Robinette CL. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988; 12: 271-86.
5. Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988; 140: 1049-53.
6. Taguchi O, Kojima A, Nishizuka Y. Experimental autoimmune prostatitis after neonatal thymectomy in the mouse. Clin Exp Immunol 1985; 60: 123-9.
7. Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, et al. Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology 2008; 71: 868-72.
8. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298 (Pt 2): 249-58.
9. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
10. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-43.
11. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
12. Baltaci S, Orhan D, Gogus C, Turkolmez K, Tulunay O, et al. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low-and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 2001; 88: 100-3.
13. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998; 82: 1897-903.
14. Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999; 189: 224-9.
15. Bosch JL, Kranse R, van Mastrigt R, Schroder FH. Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol 1995; 153: 689-93.
16. Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform 2002; 3: 146-53.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
18. Lee C, Kozlowski JM, Grayhack JT. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997; 31: 131-8.
19. Lee YC, Wu WJ, Liu CC, Wang CJ, Li WM, et al. The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. J Sex Med 2009; 6: 3158-65.
20. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992; 107: 1092-5.
21. Esumi H, Tannenbaum SR. U.S.-Japan Cooperative Cancer Research Program: seminar on nitric oxide synthase and carcinogenesis. Cancer Res 1994; 54: 297-301.
22. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-6.
23. Armour KE, Ralston SH. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology 1998; 139: 799-802.
24. Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire M P, et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril 1995; 63: 1101-7.
25. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993; 1178: 153-75.
26. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10: 2247-58.
27. Vamvakas S, Schmidt HH. Just say NO to cancer? J Natl Cancer Inst 1997; 89: 406-7.
28. Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffths JR, et al. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc Res 2006; 71: 76-84.
29. Xie K, Huang S, Dong Z, Juang SH, Wang Y, et al. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 1997; 89: 421-7.